Mendelian randomization unveils genetic causal relationships between viral infections and systemic sclerosis.

Publication date: Jul 02, 2025

This study uses Mendelian randomization (MR) to investigate the potential causal relationships between viral infections, including Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), SARS-CoV-2, cytomegalovirus (CMV), human herpes virus 6 (HHV-6), varicella-zoster virus (VZV), herpes simplex virus (HSV), influenza A virus, and hepatitis B virus, and the risk of systemic sclerosis (SSc). Summary-level data on viral exposures and SSc outcomes were obtained from public genome-wide association studies (GWAS) databases. Causality was assessed using the inverse-variance weighted (IVW), MR-Egger, and weighted median methods. Sensitivity analysis was conducted to enhance the reliability and robustness of our findings. Genetically predicted anti-EBV viral capsid antigen IgG levels (OR = 3. 400, 95% CI = 1. 093-10. 571, p = 0. 035) were causally associated with an elevated risk of SSc, while HIV (OR = 0. 787, 95% CI = 0. 629-0. 985, p = 0. 037) and SARS-CoV-2 (OR = 0. 335, 95% CI = 0. 116-0. 964, p = 0. 043) correlated with a reduced risk of SSc. Sensitivity analysis validated the robustness of these associations (p > 0. 05). Further elucidation of the underlying mechanisms by which EBV increases the risk of SSc could potentially identify interventions for promoting SSc prevention.

Open Access PDF

Concepts Keywords
Cytomegalovirus Causal relationship
Influenza COVID-19
Randomization Genome-Wide Association Study
Simplex Genome-wide association study
Humans
Mendelian randomization
Mendelian Randomization Analysis
Polymorphism, Single Nucleotide
SARS-CoV-2
Scleroderma, Systemic
Systemic sclerosis
Virus Diseases
Virus infection

Semantics

Type Source Name
disease MESH viral infections
disease MESH systemic sclerosis
disease IDO immunodeficiency
disease MESH herpes simplex
drug DRUGBANK Influenza A virus
disease MESH Causality
disease MESH influenza
disease MESH hepatitis
disease MESH fibrosis
disease MESH morbidity
disease MESH autoimmunity
disease MESH Rheumatism
drug DRUGBANK Coenzyme M
disease MESH varicella
disease MESH infections
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
drug DRUGBANK Methionine
disease IDO blood
disease MESH autoimmune diseases
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
pathway REACTOME Interferon Signaling
disease MESH EBV infection
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH infectious diseases
disease IDO host
disease MESH connective tissue diseases
disease MESH viral load
disease IDO immune response
disease MESH COVID 19
disease MESH acquired immune deficiency syndrome
pathway REACTOME Immune System
disease IDO infection
disease MESH critically ill
disease IDO acute infection
disease MESH fatal outcomes
disease IDO protein

Original Article

(Visited 3 times, 1 visits today)